Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Agenus: Rebuttal To Attack By Adam Feuerstein on the Company (AGEN, Buy, $2.85)

Report Overview
Adam Feuerstein launched a withering attack on Agenus (AGEN) and me in his column. The gist of the article…
Read more…

Agenus: Thoughts on Phase II Results for Prophage in Glioblastoma (AGEN, $2.91)

Reason for This Report
Agenus (AGEN) just issued an update on a phase II trial of Prophage G-100 combined with current…
Read more…